Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 6/20 | 0.67 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.67 |
| ▸ | GCGR | P47871 | 2/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5764416 | 1.00 | MAPK14 (0.67) | MAPK14MAPK11GCGRPARP1NPC1 | |
| SCHEMBL5763394 | 1.00 | MAPK14 (0.67) | MAPK14MAPK11GCGRPARP1NPC1 | |
| SCHEMBL6222012 | 0.96 | MAPK14 (0.65) | MAPK14MAPK11GCGRPARP1 | |
| SCHEMBL6219302 | 0.95 | MAPK14 (0.71) | MAPK14MAPK11GCGRRIPK3 | |
| SCHEMBL6220074 | 0.93 | MAPK11 (0.56) | MAPK14MAPK11PARP1 | |
| SCHEMBL5763268 | 0.91 | MAPK11 (0.55) | MAPK14MAPK11 | |
| SCHEMBL6222904 | 0.91 | MAPK14 (0.65) | MAPK14MAPK11GCGRRIPK3 | |
| SCHEMBL6218785 | 0.91 | MAPK14 (0.65) | MAPK14MAPK11GCGRCYP1A2CYP3A4 | |
| SCHEMBL6220025 | 0.91 | MAPK14 (0.65) | MAPK14MAPK11GCGRRIPK3 | |
| SCHEMBL5764180 | 0.91 | MAPK14 (0.55) | MAPK14MAPK11GCGRNPC1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050159444-A1 | Bicyclic unsaturated tertiary amine compounds | SANKYO COMPANY, LIMITED (JP) | 2005-07-21 | — | — | US | claimed |
| EP-1541571-A1 | BICYCLIC UNSATURATED TERTIARY AMINE COMPOUND | Sankyo Company, Limited (JP) | 2005-06-15 | — | — | EP | claimed |
| US-20050159444-A1 | Bicyclic unsaturated tertiary amine compounds | SANKYO COMPANY, LIMITED (JP) | 2005-07-21 | — | — | US | disclosed |
| EP-1541571-A1 | BICYCLIC UNSATURATED TERTIARY AMINE COMPOUND | Sankyo Company, Limited (JP) | 2005-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050159444-A1 | Bicyclic unsaturated tertiary amine compounds | IL1B, IL1A, STAT6 | MAPK14 340/4885MAPK11 556/4885GCGR 2036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.